Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
COPD, Cardiovascular disease, Novel Dry Powder Inhaler, Survival
Brief summary
The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.
Detailed description
Despite a potential link between the pathogenetic mechanisms involved in Chronic Obstructive Pulmonary Disease (COPD) and atherosclerotic cardiovascular disease, there are no currently approved therapies for patients with COPD that have clearly shown an additional beneficial effect in patients with cardiovascular comorbidities. The TOwards a Revolution in COPD Health (TORCH) study assessed the impact of the inhaled corticosteroid (ICS) fluticasone propionate (FP) in combination with the long-acting beta agonist (LABA), salmeterol (SAL), in reducing all-cause mortality. TORCH demonstrated a 17.5% reduction on all-cause mortality with salmeterol-fluticasone propionate combination (SFC) compared with placebo (HR=0.825, 95% CI (0.681, 1.002), p=0.052) in the entire COPD population with disease severity form moderate to very severe. A post hoc analysis of the data restricted to those subjects with an forced expiratory volume in 1 second (FEV1) \>=50% predicted with an apparent history of cardiovascular co-morbidities (defined as use at baseline of beta-blockers, angiotensin converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB), HMG CoA reductase inhibitors (i.e. statins) or a prior MI recorded at baseline) demonstrated a 49% reduction in the risk of dying within 96 weeks for the comparison of SFC with placebo. These post hoc data suggest the possibility of an ICS/LABA combination product to be of substantial benefit in COPD subjects with less severe airflow obstruction yet with increased cardiovascular risk. The mechanism by which SFC appears to be associated with a greater reduction in mortality in these less severe COPD subjects with concomitant cardiovascular comorbidities is speculative at present, but could potentially in part be related to a lessening of the degree of inflammation in the systemic circulation, potential plaque stabilization and/or amelioration of arterial stiffness. ICS/LABA combinations that are currently available require twice daily administration. A once daily ICS/LABA combination has the potential to improve patient compliance and as a result, overall disease management. The purpose of this study is to prospectively evaluate the effect of the once daily ICS/LABA combination Fluticasone Furoate (FF)/Vilanterol (VI) on survival in subjects with moderate COPD (\>=50 and =\<70 % predicted FEV1 ) and a history of, or at increased risk for cardiovascular disease.
Interventions
100/25mcg given once daily via novel dry powder inhaler
DRUGfluticasone furoate
100mcg given once daily via novel dry powder inhaler
DRUGvilanterol
25mcg given once daily via novel dry powder inhaler
OTHERPlacebo
placebo comparator once daily via novel dry powder inhaler
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Type of subject: outpatient. * Informed consent: Subjects must give their signed and dated written informed consent to participate. * Gender: Male or female. Female subjects must be post-menopausal or using a highly effective method for avoidance of pregnancy. The decision to include or exclude women of childbearing potential may be made at the discretion of the investigator in accordance with local practice in relation to adequate contraception. * Age: \>=40 and \<=80 years of age at Screening (Visit 1). * Tobacco use: Subjects with a current or prior history of \>=10 pack-years of cigarette smoking at screening (Visit 1). Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. * Airflow Obstruction: Subjects with a measured post-albuterol/salbutamol forced expiratory volume in 1 second (FEV1)/(forced vital capacity)FVC ratio of \<=0.70 at Screening (Visit 1). Subjects with a measured post-albuterol/salbutamol FEV1 \>=50 and \<=70% of predicted normal values calculated using NHANES III reference equations \[Hankinson, 1999; Hankinson, 2010\] at Screening (Visit 1). Post-bronchodilator spirometry will be performed approximately 15 minutes after the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via a metered dose inhaler (MDI )with a valved-holding chamber. The FEV1/FVC ratio and FEV1 percent predicted values will be calculated. * Symptoms of COPD: Subjects must score 2 or higher on the modified Medical Research Council Dyspnea scale (Visit 1) * Cardiovascular disease: For patients \>= 40 years of age: any one of the following: Established (i.e. by clinical signs or imaging studies) coronary artery disease (CAD) Established (i.e. by clinical signs or imaging studies) peripheral vascular disease (PVD) Previous stroke Previous MI Diabetes mellitus with target organ disease OR For patients \>=60 years of age: any 2 of the following: Being treated for hypercholesterolemia Being treated for hypertension Being treated for diabetes mellitus Being treated for peripheral vascular disease
Exclusion criteria
* Pregnancy: Women who are pregnant or lactating. * Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they also have a current diagnosis of COPD). * alpha 1-antitrypsin deficiency: Subjects with known alpha-1 antitrypsin deficiency as the underlying cause of COPD. * Other respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases. * Lung resection or transplantation: Subjects with lung volume reduction surgery within the 12 months prior to Screening or having had a lung transplant. * A moderate/severe COPD exacerbation that has not resolved at least 14 days prior to Visit 1 and at least 30 days following the last dose of oral corticosteroids (if applicable). * Current severe heart failure (New York Heart Association class IV). Subjects will also be excluded if they have a known ejection fraction of \<30% or if they have an implantable cardioverter defibrillator (ICD). * Other diseases/abnormalities: Any life-threatening condition with life expectancy \<3 years, other than vascular disease or COPD, that might prevent the subject from completing the study. * End stage chronic renal disease: Subjects will be excluded if on renal replacement therapy (hemodialysis or peritoneal). * Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g. beta-agonists, corticosteroid) or components of the inhalation powder (e.g. lactose, magnesium stearate). In addition, patients with a history of severe milk protein allergy that, in the opinion of the study physician, contraindicates the subject's participation will also be excluded. * Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years. * Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use (i.e. \<=12 hours per day) is not exclusionary. * Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of informed consent to participate in the study or the potential compliance to study procedures. * Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study. * Additional medication: Use of the following medications within the following time intervals prior to Visit 1 or during the study (unless otherwise specified): Medication No use within the following time intervals prior to Screening or thereafter at any time during the study (unless otherwise specified) Inhaled Long acting beta-agonists (LABA) 48 hours ICS/LABA combination products 48 hours Inhaled corticosteroids 48 hours Tiotropium 1 week Systemic, Oral, parenteral, intra-articular corticosteroids 30 days (oral and systemic corticosteroids may be used to treat COPD exacerbations during the study) Cytochrome P450 3A4 strong inhibitors including but not limited to antiretrovirals (protease inhibitors) (e.g.Indinavir, Nelfinavir, Ritonavir, Saquinavir); Imidazole and Triazole anti-fungals (e.g. Ketaconazole, Itraconazole); Clarithromycin, Telithromycin, Amiodarone, and Nefazodone 6 weeks Grapefruit is allowed up to Visit 1, then limited to no more than one glass of grapefruit juice (250 mL/ 8 ounces) or one grapefruit per day Any other investigational drug 30 days or 5 half lives whichever is longer.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date | From the date of randomization until date of death due to any cause (average of 2 study years) | Death from any cause: which occurred from the day of starting IP until the Commone End Date (CED). Common End Date (CED) is the study end date that was pre determined where approximately 1000 deaths would have occurred in the Intent-toTreat Efficacy (ITT-E) Population. Only deaths which occurred on or before the CED were used for the primary analysis. Those who had not died by CED, but who were known to be alive on or after the CED, were censored at the CED. Cox Proportional Hazards (PH) Model was adjusted for age, and gender, including all 4 arms. A hazard ratio of less than 1 indicates a lower death rate versus placebo or other arm. ITT-E Population consisted of all participants in the Safety Population (i.e. randomized to IP and who received at least one dose of IP), with the exception of those recruited at sites that were closed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Decline in Forced Expiratory Volume in 1 Second (FEV1) | From start date of IP until IP stop date + 1 (assessed up to 4 years) | FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The effect of treatment on decline of post bronchodilator FEV1 recorded during the treatment period was analyzed using a particular form of a mixed effect model - a random coefficients model. FEV1 was fitted as the response variable with treatment group, age, gender, baseline FEV1 and time on treatment as fixed effects. Time on treatment was treated as a continuous variable. This model allowed for an initial increase in FEV1, but then tested the difference in slopes from the first post-baseline measurement which was at 3 months. A negative slope indicates a decline. A positive treatment difference indicates a slower rate of decline vs Placebo or Component. Only participants with at least one on-treatment post-bronchodilator FEV1 measurement were analyzed. |
| Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date | From the start of IP to first on treatment CV event till 7 days after the last dose of IP (average of 2 study years) | On-treatment CV composite event is comprised of the first event that is adjudicated as on-treatment CV death, myocardial infarction, stroke, unstable angina, or transient ischemic attack experienced by a participant. The events that occurred no more than 7 days after the participants last dose of IP are considered as on-treatment adverse events. Common end date is the study end date where approximately 1000 deaths would have occurred in the ITT-E Population. Cox PH Model was used to assess time to first on-treatment CV composite event. Cox PH Model was adjusted for age, gender and indicators of ischemic and vascular disease, including all four treatment arms. A hazard ratio less than 1 indicates a lower risk of a first CV event rate versus placebo or any arm. |
Countries
Argentina, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, France, Georgia, Germany, Greece, Hungary, India, Indonesia, Israel, Italy, Japan, Latvia, Malaysia, Mexico, Netherlands, North Macedonia, Philippines, Poland, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States, Vietnam
Participant flow
Recruitment details
This study was conducted at 1373 sites. The study employed an event-driven design and was to conclude when approximately 1000 reports of a primary outcome event of death were received. The study consisted of a 4-10 day run-in period, variable treatment period until the required number of events was achieved, and 1 week follow-up period.
Pre-assignment details
A total of 23,835 participants were screened, of whom 16,590 were randomized. Of the 16,590 participants randomized, 16,568 participants received a single dose of investigational product (IP) and were assigned to a treatment and included in the Safety Population.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants received placebo once daily (OD) in the morning from the dry powder inhaler (DPI) until the required number of events (death) was achieved. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period. | 4,131 |
| Fluticasone Furoate 100 µg Participants received Fluticasone Furoate (FF) 100 microgram (µg) inhalation powder OD in the morning from the DPI until the required number of events (death) was achieved. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period. | 4,157 |
| Vilanterol 25 µg Participants received Vilanterol (VI) 25 µg inhalation powder OD in the morning from the DPI until the required number of events (death) was achieved. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period. | 4,140 |
| Fluticasone Furoate/Vilanterol 100/25 µg Participants received FF/VI 100/25 µg inhalation powder OD in the morning from the DPI until the required number of events (death) was achieved. Participants were provided albuterol/salbutamol inhalation aerosol to be used as rescue medication during the Treatment Period. | 4,140 |
| Total | 16,568 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 395 | 365 | 372 | 333 |
| Overall Study | Decision by Participant or Proxy | 643 | 527 | 515 | 492 |
| Overall Study | Investigator Site Closed | 12 | 11 | 15 | 10 |
| Overall Study | Lack of Efficacy | 98 | 90 | 65 | 46 |
| Overall Study | Lost to Follow-up | 0 | 0 | 1 | 0 |
| Overall Study | Met Protocol-Defined Stopping Critera | 3 | 4 | 2 | 11 |
| Overall Study | Missing | 1 | 1 | 1 | 0 |
| Overall Study | Physician Decision | 53 | 64 | 62 | 48 |
| Overall Study | Protocol Violation | 37 | 44 | 46 | 44 |
| Overall Study | Sponsor Terminated Study Treatment | 1 | 1 | 0 | 1 |
| Overall Study | Study Closed/terminated | 7 | 6 | 9 | 9 |
Baseline characteristics
| Characteristic | Placebo | Total | Fluticasone Furoate/Vilanterol 100/25 µg | Vilanterol 25 µg | Fluticasone Furoate 100 µg |
|---|---|---|---|---|---|
| Age, Continuous | 65.2 Years STANDARD_DEVIATION 7.9 | 65.2 Years STANDARD_DEVIATION 7.89 | 65.3 Years STANDARD_DEVIATION 7.97 | 65.2 Years STANDARD_DEVIATION 7.68 | 65.0 Years STANDARD_DEVIATION 8.02 |
| Race/Ethnicity, Customized African American /African Heritage | 61 Participants | 260 Participants | 69 Participants | 68 Participants | 62 Participants |
| Race/Ethnicity, Customized American Indian or Alaskan Native | 9 Participants | 27 Participants | 9 Participants | 4 Participants | 5 Participants |
| Race/Ethnicity, Customized Asian - Central /South Asian Heritage | 64 Participants | 238 Participants | 57 Participants | 62 Participants | 55 Participants |
| Race/Ethnicity, Customized Asian - East Asian Heritage | 192 Participants | 772 Participants | 192 Participants | 195 Participants | 193 Participants |
| Race/Ethnicity, Customized Asian - Japanese Heritage | 34 Participants | 144 Participants | 37 Participants | 37 Participants | 36 Participants |
| Race/Ethnicity, Customized Asian - Mixed Race | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian - South East Asian Heritage | 389 Participants | 1568 Participants | 394 Participants | 386 Participants | 399 Participants |
| Race/Ethnicity, Customized Mixed Race | 32 Participants | 115 Participants | 30 Participants | 28 Participants | 25 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 1 Participants | 5 Participants | 2 Participants | 0 Participants | 2 Participants |
| Race/Ethnicity, Customized White - Arabic/North African Heritage | 14 Participants | 46 Participants | 12 Participants | 7 Participants | 13 Participants |
| Race/Ethnicity, Customized White - Mixed Race | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized White - White/Caucasian /European Heritage | 3334 Participants | 13391 Participants | 3337 Participants | 3353 Participants | 3367 Participants |
| Sex: Female, Male Female | 1050 Participants | 4238 Participants | 1019 Participants | 1071 Participants | 1098 Participants |
| Sex: Female, Male Male | 3081 Participants | 12330 Participants | 3121 Participants | 3069 Participants | 3059 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 1,862 / 4,131 | 1,941 / 4,157 | 1,827 / 4,140 | 1,761 / 4,140 |
| serious Total, serious adverse events | 918 / 4,131 | 929 / 4,157 | 972 / 4,140 | 961 / 4,140 |
Outcome results
Primary
Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date
Death from any cause: which occurred from the day of starting IP until the Commone End Date (CED). Common End Date (CED) is the study end date that was pre determined where approximately 1000 deaths would have occurred in the Intent-toTreat Efficacy (ITT-E) Population. Only deaths which occurred on or before the CED were used for the primary analysis. Those who had not died by CED, but who were known to be alive on or after the CED, were censored at the CED. Cox Proportional Hazards (PH) Model was adjusted for age, and gender, including all 4 arms. A hazard ratio of less than 1 indicates a lower death rate versus placebo or other arm. ITT-E Population consisted of all participants in the Safety Population (i.e. randomized to IP and who received at least one dose of IP), with the exception of those recruited at sites that were closed.
Time frame: From the date of randomization until date of death due to any cause (average of 2 study years)
Population: ITT-E Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date | Dead | 275 Participants |
| Placebo | Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date | Unknown | 4 Participants |
| Placebo | Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date | Alive | 3832 Participants |
| Fluticasone Furoate 100 µg | Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date | Dead | 251 Participants |
| Fluticasone Furoate 100 µg | Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date | Unknown | 0 Participants |
| Fluticasone Furoate 100 µg | Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date | Alive | 3884 Participants |
| Vilanterol 25 µg | Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date | Alive | 3853 Participants |
| Vilanterol 25 µg | Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date | Dead | 265 Participants |
| Vilanterol 25 µg | Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date | Unknown | 0 Participants |
| Fluticasone Furoate/Vilanterol 100/25 µg | Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date | Dead | 246 Participants |
| Fluticasone Furoate/Vilanterol 100/25 µg | Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date | Unknown | 1 Participants |
| Fluticasone Furoate/Vilanterol 100/25 µg | Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date | Alive | 3874 Participants |
p-value: 0.13795% CI: [0.739, 1.042]Cox Proportional Hazards Model
95% CI: [-4.2, 26.1]
p-value: 0.28495% CI: [0.767, 1.081]Cox Proportional Hazards Model
95% CI: [-8.1, 23.3]
p-value: 0.65595% CI: [0.813, 1.139]Cox Proportional Hazards Model
95% CI: [-13.9, 18.7]
p-value: 0.68195% CI: [0.808, 1.149]Cox Proportional Hazards Model
95% CI: [-14.9, 19.2]
p-value: 0.29995% CI: [0.767, 1.085]Cox Proportional Hazards Model
95% CI: [-8.5, 23.3]
Secondary
Decline in Forced Expiratory Volume in 1 Second (FEV1)
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The effect of treatment on decline of post bronchodilator FEV1 recorded during the treatment period was analyzed using a particular form of a mixed effect model - a random coefficients model. FEV1 was fitted as the response variable with treatment group, age, gender, baseline FEV1 and time on treatment as fixed effects. Time on treatment was treated as a continuous variable. This model allowed for an initial increase in FEV1, but then tested the difference in slopes from the first post-baseline measurement which was at 3 months. A negative slope indicates a decline. A positive treatment difference indicates a slower rate of decline vs Placebo or Component. Only participants with at least one on-treatment post-bronchodilator FEV1 measurement were analyzed.
Time frame: From start date of IP until IP stop date + 1 (assessed up to 4 years)
Population: ITT-E Population
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Decline in Forced Expiratory Volume in 1 Second (FEV1) | -46 milliliter/year | Standard Error 2.5 |
| Fluticasone Furoate 100 µg | Decline in Forced Expiratory Volume in 1 Second (FEV1) | -38 milliliter/year | Standard Error 2.4 |
| Vilanterol 25 µg | Decline in Forced Expiratory Volume in 1 Second (FEV1) | -47 milliliter/year | Standard Error 2.4 |
| Fluticasone Furoate/Vilanterol 100/25 µg | Decline in Forced Expiratory Volume in 1 Second (FEV1) | -38 milliliter/year | Standard Error 2.4 |
p-value: 0.01995% CI: [1, 15]Mixed Models Analysis
p-value: 0.02695% CI: [1, 14]Mixed Models Analysis
p-value: 0.65495% CI: [-8, 5]Mixed Models Analysis
p-value: 0.91395% CI: [-6, 7]Mixed Models Analysis
p-value: 0.00495% CI: [3, 16]Mixed Models Analysis
Secondary
Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date
On-treatment CV composite event is comprised of the first event that is adjudicated as on-treatment CV death, myocardial infarction, stroke, unstable angina, or transient ischemic attack experienced by a participant. The events that occurred no more than 7 days after the participants last dose of IP are considered as on-treatment adverse events. Common end date is the study end date where approximately 1000 deaths would have occurred in the ITT-E Population. Cox PH Model was used to assess time to first on-treatment CV composite event. Cox PH Model was adjusted for age, gender and indicators of ischemic and vascular disease, including all four treatment arms. A hazard ratio less than 1 indicates a lower risk of a first CV event rate versus placebo or any arm.
Time frame: From the start of IP to first on treatment CV event till 7 days after the last dose of IP (average of 2 study years)
Population: ITT-E Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date | Had CV composite event | 173 Participants |
| Placebo | Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date | No CV composite event | 3938 Participants |
| Fluticasone Furoate 100 µg | Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date | No CV composite event | 3974 Participants |
| Fluticasone Furoate 100 µg | Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date | Had CV composite event | 161 Participants |
| Vilanterol 25 µg | Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date | Had CV composite event | 180 Participants |
| Vilanterol 25 µg | Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date | No CV composite event | 3938 Participants |
| Fluticasone Furoate/Vilanterol 100/25 µg | Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date | Had CV composite event | 174 Participants |
| Fluticasone Furoate/Vilanterol 100/25 µg | Number of Participants With First On-treatment Cardiovascular (CV) Composite Events Occured on or Before Common End Date | No CV composite event | 3947 Participants |
p-value: 0.47595% CI: [0.75, 1.143]Cox Proportional Hazards Model
95% CI: [-14.3, 25]
p-value: 0.31795% CI: [0.723, 1.111]Cox Proportional Hazards Model
95% CI: [-11.1, 27.7]
p-value: 0.90895% CI: [0.802, 1.217]Cox Proportional Hazards Model
95% CI: [-21.7, 19.8]
p-value: 0.76395% CI: [0.834, 1.281]Cox Proportional Hazards Model
95% CI: [-28.1, 16.6]
p-value: 0.54595% CI: [0.761, 1.155]Cox Proportional Hazards Model
95% CI: [-15.5, 23.9]